Charles Schwab Investment Management Inc. lifted its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,016,533 shares of the company's stock after purchasing an additional 13,395 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.82% of Guardant Health worth $31,055,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Jones Financial Companies Lllp grew its stake in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares during the period. Fiduciary Alliance LLC boosted its stake in Guardant Health by 7.6% in the 4th quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after buying an additional 836 shares in the last quarter. R Squared Ltd bought a new stake in Guardant Health in the fourth quarter valued at $26,000. Van ECK Associates Corp raised its stake in Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock worth $88,000 after acquiring an additional 929 shares in the last quarter. Finally, Wexford Capital LP lifted its holdings in shares of Guardant Health by 13.0% during the third quarter. Wexford Capital LP now owns 10,081 shares of the company's stock valued at $231,000 after acquiring an additional 1,158 shares during the period. 92.60% of the stock is currently owned by institutional investors.
Guardant Health Stock Performance
NASDAQ:GH traded down $1.43 during mid-day trading on Thursday, hitting $44.81. The company had a trading volume of 1,556,217 shares, compared to its average volume of 2,139,023. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The firm has a market cap of $5.53 billion, a P/E ratio of -12.74 and a beta of 1.50. The business's fifty day moving average is $43.50 and its two-hundred day moving average is $33.28.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Equities analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on GH shares. The Goldman Sachs Group increased their target price on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Scotiabank lifted their target price on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. JPMorgan Chase & Co. increased their price target on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Piper Sandler lifted their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Raymond James reissued an "outperform" rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $48.40.
Check Out Our Latest Stock Analysis on Guardant Health
Guardant Health Company Profile
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
See Also
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
